Hemocompatibility

Hemocompatibility is the property of a material or device to perform similarly in contact with blood without causing adverse biological responses. It is a central concern for any medical device that directly or indirectly interfaces with blood, such as catheters, vascular grafts, stents, artificial heart valves, and extracorporeal circulation systems. The goal is to minimize coagulation, inflammation, hemolysis, and immune activation while maintaining device function.

Blood contact can trigger multiple pathways: protein adsorption to surfaces, platelet adhesion and activation, triggering of the coagulation cascade, activation of the complement system, and inflammatory responses. These reactions may lead to thrombosis, embolism, bleeding complications, or damage to blood cells and tissues. Hemolysis, a mechanical or chemical destruction of red blood cells, is another potential adverse outcome.

Assessment combines in vitro and in vivo methods. In vitro tests evaluate hemolysis, clotting times, platelet adhesion and aggregation, thrombin generation, and complement activation, often on representative surfaces. Surface characterization and protein adsorption studies aid interpretation. In vivo testing in animal models provides integrated information on thrombogenicity and inflammatory responses. Regulatory guidance from bodies such as the ISO 10993 series and standards like ASTM F756 informs a risk-based biocompatibility evaluation.

Design strategies to improve hemocompatibility include surface modifications such as heparin coatings, hydrophilic or zwitterionic polymers, and nitric oxide–releasing coatings, as well as careful control of roughness and chemistry. Flow dynamics and device geometry also influence blood-material interactions. Selection of materials and coatings depends on the intended duration and nature of blood contact.

Clinical adoption requires rigorous testing, documentation, and adherence to applicable standards to demonstrate safety and performance for the intended use.